Advertisement
Screener

TENAX THERAPEUTICS, INC. (TENX) Amortization of Debt Issuance Costs

2.0 / 5 stars · 17/43 Roast Me

TENAX THERAPEUTICS, INC. Amortization of Debt Issuance Costs

TENAX THERAPEUTICS, INC. (TENX) reported Amortization of Debt Issuance Costs of $128.62 thousand for the 12-month period ending 2013-04-30, per its 10-K filed 2013-06-26.

Discontinued › Expense Statement › Operating Expenses

us-gaap:AmortizationOfFinancingCosts · last filed 2013-06-26

  • TENAX THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-04-30 was $32.15K, a 200.00% increase year-over-year.
  • TENAX THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-01-31 was $32.15K, a 0.00% change year-over-year.
  • TENAX THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2012-10-31 was $32.15K, a 0.00% change year-over-year.
  • TENAX THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2012-07-31 was $32.15K, a 200.00% increase year-over-year.
  • TENAX THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2013 was $128.62K, a 20.00% increase from fiscal 2012.
  • TENAX THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2012 was $107.18K.
Period endAmortization of Debt Issuance Costs 3 monthAmortization of Debt Issuance Costs 6 monthAmortization of Debt Issuance Costs 9 monthAmortization of Debt Issuance Costs 12 month
2013-04-30$32.15K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-26
$64.31K
derived: sum of 2 quarters · filed 2013-06-26
$96.46K
derived: sum of 3 quarters · filed 2013-06-26
$128.62K
10-K · filed 2013-06-26
2013-01-31$32.15K
10-Q · filed 2013-03-18
$64.31K
derived: sum of 2 quarters · filed 2013-03-18
$96.46K
10-Q · filed 2013-03-18
$107.18K
derived: sum of 4 quarters · filed 2013-06-26
2012-10-31$32.15K
10-Q · filed 2012-12-14
$64.31K
10-Q · filed 2012-12-14
$75.03K
derived: sum of 3 quarters · filed 2013-06-26
$107.18K
derived: sum of 4 quarters · filed 2013-06-26
2012-07-31$32.15K
10-Q · filed 2012-09-19
$42.87K
derived: sum of 2 quarters · filed 2013-06-26
$75.03K
derived: sum of 3 quarters · filed 2013-06-26
$107.18K
derived: sum of 4 quarters · filed 2013-06-26
2012-04-30$10.72K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-26
$42.87K
derived: sum of 2 quarters · filed 2013-06-26
$75.03K
derived: sum of 3 quarters · filed 2013-06-26
$107.18K
10-K · filed 2013-06-26
2012-01-31$32.15K
10-Q · filed 2013-03-18
$64.31K
derived: sum of 2 quarters · filed 2013-03-18
$96.46K
10-Q · filed 2013-03-18
2011-10-31$32.15K
10-Q · filed 2012-12-14
$64.31K
10-Q · filed 2012-12-14
2011-07-31$10.72K
10-Q · filed 2012-09-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Cingulate Inc. (CING)United States$0.073B-2.64
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
XBiotech Inc. (XBIT)United States$0.066B-1.56
OS Therapies Inc (OSTX)United States$0.076B-2.17